In Vivo Evaluation Using Gamma Scintigraphy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

In Vivo Evaluation Using Gamma Scintigraphy
The authors discuss gamma scintigraphy as a technique for in vivo evaluation of drugs and delivery systems.


Pharmaceutical Technology


References

1. S. Jain, P. Dani, and R.K. Sharma, Crit. Rev. Ther. Drug 26 (4), 373–426 (2009).

2. S.P. Newman, P.H. Hirst, and I.R. Wilding, Eur. J. Pharm. Sci. 18 (1), 19–22 (2003).

3. Y.S.R. Krishnaina, S. Satyanarayana, and Y.V. Rama Prasad, J. Pharm. Sci. 5 (1), 24–28 (2002).

4. C.G. Wilson and N. Washington, "Gamma Scinitigraphy in the Analysis of the Behavior of Controlled Release Systems," in Handbook of Pharmaceutical Controlled Release Technology (Marcel Dekker, New York, 1st ed., 2005), pp. 551–565.

5. N.K. Jain, "Colon-Specific Drug Delivery Systems," in Advances in Controlled and Novel Drug Delivery (CBS Publishers, New Delhi, India, 1st ed., 2006), pp. 104–109.

6. I.R. Wilding, A.J. Coupe, and S.S. Davis, Adv. Drug. Deliver. Rev. 46 (1), 103–124 (2001).

7. "H.F. Solomn, H.D. Burns, and R.E. Gibson, Drug. Dev. Ind. Pharm. 16 (18), 2655–2673 (1990).

8. G. Meseguer, R. Gurny, and P. Buri, J. Drug Target. 2 (4), 269–288 (1994).

9. A.W. Basit et al., Eur. J. Pharm. Sci. 21 (2–23), 179–189 (2004).

10. "Methods of Radiolabeling," Quotient Bioresearch (Cambridgeshire, UK), http://www.quotientbioresearch.com/methods-radiolabeling/, accessed Oct. 18, 2010.

12. G.A. Digenis, E.P. Sandefer, R.C. Page, and W.J. Doll, Pharm. Sci. Technol. Today, 1 (3), 100–107 (1998).

13. L. Yang, J.S. Chu, and J.A. Fix, "Int. J. Pharm. 235 (1–2), 1–15 (2002).

14. S. Connolly, CRS Newlsetter 25 (4), 16–17 (2008).

15. M.S. Berridges, D.L. Heald, and Z. Lee, Drug. Dev. Res. 59 (2), 208–209 (2003).

16. K. Jones, "New Technology Combo Drives Once-Daily Drug Formulation," http://www.iptonline.com/articles/public/IPT_26_p66nonprint.pdf, accessed Sept. 27, 2010.

17. A.K. Singh, N. Bhardwaj, and A. Bhatnagar, Indian J. Pharm. Sci. 66 (1), 18–25 (2004).

18. "Pharmacoscintigraphy," Quotient Bioresearch (Cambridgeshire, UK), http://www.quotientbioresearch.com/pharmacoscintigraphy, accessed Oct. 18, 2010.

19. P.P. Hazari, et al., Bioconjugate. Chem. 21 (2), 229–239 (2010).

20. A. Pathak et al., ACS. Nano. 3 (6), 1493–1505 (2009).

21. D. Wang et al., Mol. Pharm. 3 (6), 717–725 (2006).

22. IAEA, "Radiation Protection Procedures," in International Atomic Energy Agency Safety Series (New York, 1978).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here